Premium
CHRONIC DOPAMINE RECEPTOR STIMULATION USING BROMOCRIPTINE: FAILURE TO MODIFY THYROID FUNCTION
Author(s) -
KÖBBERLING J.,
DARRAGH A.,
POZO E. DEL
Publication year - 1979
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1979.tb03087.x
Subject(s) - bromocriptine , medicine , endocrinology , dopamine agonist , dopaminergic , agonist , dopamine , dopamine receptor , stimulation , basal (medicine) , thyroid function , receptor , thyroid , prolactin , hormone , diabetes mellitus
SUMMARY Administration of 2.5 mg bromocriptine (Parlodel), a dopamine agonist, on two occasions to six normal volunteers did not alter the plasma TSH response to an i.v. injection of 100 μg TRH, but significantly (P < 0.01) blunted it after 200 μ g . Chronic bromocriptine treatment (7.5–50 mg/day) of fifteen acromegalic subjects failed to influence basal plasma TSH or the response pattern to 200 μ g TRH. The thyroxine Binding Index (TBI) and the levels of T3 and T4 were not modified by treatment. These results indicate that chronic dopaminergic therapy with bromocriptine does not alter thyroid function.